Jim Cramer's Hottest GLP-1 and Weight Loss Stock Picks
In an appearance on CNBC's Fast Money in January, Ray Stevens, CEO of Structure Therapeutics, discussed the unmet potential in the obesity market.
Terns Pharmaceuticals Inc. (TERN)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Adage Capital Management Phill Gross And Robert Atchinson | 5,550,000 | $224,220,000 | +41% | 0.34% |
| 2. | Vivo Capital Albert Cha And Frank Kung | 5,346,928 | $216,015,891 | -23% | 13.96% |
| 3. | Vestal Point Capital Ryan Wilder | 4,500,000 | $181,800,000 | 6.18% | |
| 4. | VenBio Select Advisor Kurt Von Emster | 4,350,000 | $175,740,000 | 1.73% | |
| 5. | Citadel Investment Group Ken Griffin | 3,166,642 | $127,932,337 | +100% | 0.02% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $3.93 | 5,000 | $19,649.50 | 25,000 | 2025-06-27 | Filing | |
| $3.93 | 5,000 | $19,633.50 | 20,000 | 2025-06-27 | Filing | |
| $3.87 | 23,314 | $90,229.84 | 47,083 | 2025-06-25 | Filing | |
| $3.95 | 5,000 | $19,732.50 | 15,000 | 2025-06-16 | Filing | |
| $3.72 | 5,000 | $18,600.00 | 10,000 | 2025-06-13 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $47.30 | 2,770 | $131,027.65 | 288,976 | 2026-03-16 | Filing | |
| $46.57 | 11,813 | $550,080.61 | 291,746 | 2026-03-16 | Filing | |
| $39.80 | 4,083 | $162,501.36 | 288,976 | 2026-02-17 | Filing | |
| $39.22 | 8,159 | $319,963.34 | 293,059 | 2026-02-17 | Filing | |
| $38.07 | 2,341 | $89,114.38 | 301,218 | 2026-02-17 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 8,194,218 | $331,046,406 | 0.01% | |
| 2. | 7,945,608 | $321,002,599 | 0.02% | |
| 3. | 5,523,948 | $223,167,499 | 0% | |
| 4. | 3,379,569 | $136,495,568 | 0.06% | |
| 5. | 3,045,200 | $123,026,080 | 0.73% |
News See All
Analyst Optimistic on Terns (TERN) Citing Possible $4.8B Market for Upcoming Leukemia Drug
Terns Pharmaceuticals Inc. (NASDAQ:TERN) is one of 15 stocks with the biggest hedge fund momentum, after gaining 42 hedge fund holders during the fourth quarter of 2025.
15 Stocks with the Biggest Hedge Fund Momentum
On February 23, Bloomberg News reported that during the week ended February 19, hedge funds registered record-high net sales of global stocks, the highest since early April 2025.
Terns Pharmaceuticals (TERN) Eyes Expansion Beyond China Amid Strong Analyst Sentiment
On January 16, 2026, Terns Pharmaceuticals, Inc.
11 Best Performing Stocks in the Last 12 Months
The year 2025 was not just another year but a period marked by sharp shifts in technology, geopolitics, and trade policy, often driving markets in surprising ways, according to Reuters' year-end report...
Wall Street Forecasts 42.31% Upside To Terns Pharmaceuticals, Inc. (TERN)
Terns Pharmaceuticals, Inc. (NASDAQ:TERN) is among the 14 best booming stocks to buy right now.
14 Best Booming Stocks to Buy Right Now
In a report released on January 9, Goldman Sachs said that it expects the index to rally 12% in 2026.
Citizens Maintains An Outperform Rating On Terns Pharmaceuticals, Inc. (TERN)
On December 11, 2025, TheFly reported that Citizens boosted its price goal for Terns Pharmaceuticals, Inc. (NASDAQ:TERN) to $57 from $35.
Tern Pharmaceuticals (TERN) Soars 630% on CML Treatment Best-in-Class Potential
Terns Pharmaceuticals climbed by 629.64 percent in 2025, primarily boosted by stellar results from the clinical trial of its therapy candidate for chronic myeloid leukemia (CML), which has the potential...
Hedge Fund Resource Center